Markers of DNA copy number alteration for improved prognostication in prostate cancer
US7638278B2 · kind B2 · utility
16Cited by
3References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2006 |
| Grant date | Dec 29, 2009 |
| Priority date | — |
| Expiry date | Mar 1, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/112
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention describes DNA copy number alterations (CNAs), identifiable by technologies such as array-based comparative genomic hybridization (array CGH) or fluorescence in situ hybridization (FISH), that define distinct genetic subtypes of prostate cancer, and are useful for improved prognostication and treatment stratification for patients with prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.